BRUIN
Jaypirca Demonstrates Superior Efficacy Over Imbruvica in BTK Inhibitor Clash for CLL/SLL
Jaypirca; Imbruvica; BTK inhibitor; chronic lymphocytic leukemia; small lymphocytic lymphoma; BRUIN CLL-314; overall response rate; progression-free survival; head-to-head trial; Eli Lilly